ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

VYGR Voyager Therapeutics Inc

8.81
0.28 (3.28%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Voyager Therapeutics Inc VYGR NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.28 3.28% 8.81 14:00:09
Open Price Low Price High Price Close Price Previous Close
8.76 8.61 8.92 8.81 8.53
more quote information »

Recent News

Date Time Source Heading
23/4/202406:30GLOBEVoyager Therapeutics to Present Broad Set of Translational..
16/4/202421:00GLOBEVoyager Therapeutics Announces Selection of Development..
27/3/202407:01GLOBEVoyager Therapeutics Announces Inducement Grants Under..
13/3/202422:00GLOBEVoyager Therapeutics Announces Appointment of Toby Ferguson..
29/2/202408:01GLOBEVoyager Therapeutics Reports Fourth Quarter and Full Year..
29/2/202408:00EDGAR2Form 8-K - Current report
26/2/202423:00GLOBEVoyager Therapeutics Announces Selection of Gene Therapy..
23/2/202408:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202407:16EDGAR2Form 144 - Report of proposed sale of securities
22/2/202407:13EDGAR2Form 144 - Report of proposed sale of securities
21/2/202423:00GLOBEVoyager Therapeutics Announces Fourth Quarter 2023..
21/2/202407:11EDGAR2Form 144 - Report of proposed sale of securities
20/2/202423:00GLOBEVoyager Therapeutics Reports Robust Preclinical Activity in..
17/2/202409:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202409:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202409:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202423:00GLOBEVoyager Therapeutics to Present at the Oppenheimer Annual..
20/1/202408:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/1/202408:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202408:20EDGAR2Form D - Notice of Exempt Offering of Securities
18/1/202407:33EDGAR2Form 144 - Report of proposed sale of securities
18/1/202407:21EDGAR2Form 144 - Report of proposed sale of securities
09/1/202408:49EDGAR2Form 8-K - Current report
09/1/202408:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/1/202414:45GLOBEVoyager Therapeutics Announces Pricing of Public Offering
05/1/202409:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/1/202408:14GLOBEVoyager Therapeutics Announces Proposed Public Offering
03/1/202423:00GLOBEVoyager Therapeutics to Present at the 42nd Annual J.P...
02/1/202423:46DJNVoyager Therapeutics Shares Leap Premarket on Novartis..
02/1/202423:05EDGAR2Form 8-K - Current report
02/1/202423:00GLOBEVoyager Therapeutics Enters Capsid License Agreement and..
06/12/202323:04EDGAR2Form 8-K - Current report
06/12/202323:00GLOBEVoyager Therapeutics Announces Selection of Development..
07/11/202308:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202308:01GLOBEVoyager Therapeutics Reports Third Quarter 2023 Financial..
07/11/202308:00EDGAR2Form 8-K - Current report
30/10/202322:00GLOBEVoyager Therapeutics Announces Third Quarter 2023 Conference..
03/10/202307:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202321:00GLOBEVoyager Therapeutics to Present at the Chardan Genetic..
19/9/202306:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/9/202303:57EDGAR2Form 144 - Report of proposed sale of securities
08/9/202306:01GLOBEVoyager Therapeutics Announces Inducement Grants Under..
30/8/202321:00GLOBEVoyager Therapeutics to Participate in Upcoming Investor..
17/8/202306:18EDGAR2Form 8-K - Current report
09/8/202306:01GLOBEVoyager Therapeutics Announces Inducement Grants Under..
07/8/202322:00GLOBEVoyager Therapeutics Announces Appointment of Beth Shafer as..
03/8/202321:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202321:00EDGAR2Form 8-K - Current report
03/8/202321:00GLOBEVoyager Therapeutics Reports Second Quarter 2023 Financial..

Your Recent History

Delayed Upgrade Clock